Remove Books Remove Medicare Remove Prescription Drug Pricing Remove Public Health
article thumbnail

A Health Consumer Bill of Rights: Assuring Affordability, Access, Autonomy, and Equity

Jane Sarashon

In addition to highlighting the Patient’s Bill of Rights, NABIP’s keynotes and general sessions will speak to similar topics being brainstormed at VIVE this week — including mental health, maternal health, pharmacy and prescription drugs (pricing, PBMs), population health, and Medicare and Medicaid innovations.

ACA 118
article thumbnail

Hall Render’s Health Provider News – February 25, 2022

Hall Render

How 5 health systems are spending their innovation investment dollars. The 55 hospitals penalized by Medicare 8 years straight over patient complications. U of California, Irvine to Launch Institute for Precision Health. Pandemic’s mental health crisis shows California needs to reinvent health care.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The 2020 Social Determinants of Health: Connectivity, Art, Air and Love

Health Populi

A few of the mainstreaming-of-SDoH signposts in 2019 were: Cigna studying and focusing in on loneliness as a health and wellness risk factor. Humana’s Bold Goal initiative targeting Medicare Advantage enrollees. In 2019, there was a major sentinel event for public health made by a huge private sector force in America: Walmart.

article thumbnail

KFF Health News' 'What the Health?': Health Enters the Presidential Race

Kaiser Health News

Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” Jessie Hellmann: North Carolina Health News’ “ Congenital Syphilis — An Ancient Scourge — Claimed the Lives of Eight NC Babies Last Year ,” by Jennifer Fernandez.

article thumbnail

The 2020 Health Populi TrendCast – HealthConsuming, TechLash, and Public Health Goes Private

Health Populi

With the emergence of six-to-seven figure specialty drugs coming out of the Rx pipeline into commerce, we can expect growing financial toxicity as a side effect of these therapies, and evolving financial services offered to patients to pay, say, on an installment plan as Bluebird Therapeutics has offered (specifically, $1.78